Polymer-and polymer blend-bioceramic composite implantable medical devices

• US 8,343,530 B2
• Filed: 12/22/2006
• Issued: 01/01/2013
• Est. Priority Date: 05/30/2006
• Status: Expired due to Fees

• Current Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories Incorporated)
• Inventors: Wang, Yunbing, Gale, David C.
• Primary Examiner(s): AZPURU, CARLOS A
• Application Number:
  US11/644,852
• Publication Number:
  US 20070282426A1
• Time in Patent Office: 2,202 Days
• Field of Search: None
• US Class Current: 424/426
• CPC Class Codes: A61L 31/127 containing fillers of phosphorus-containing inorganic materials
• CPC Class Codes: A61L 31/128 containing other specific inorganic fillers not covered by A61L31/126 or A61L31/127
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence

Abstract

Implantable medical devices fabricated from polymer/bioceramic composites and polymer blend/bioceramic composites are disclosed.

Claims

1. An implantable medical device comprising a stent composed of a scaffolding including a pattern of interconnecting struts fabricated from a bioceramic/polymer composite, the composite comprising:

a continuous phase comprising a matrix copolymer of L-lactide and glycolide, a majority of the copolymer comprising L-lactide; and

a discrete phase within the continuous phase, the discrete phase comprising a modifier polymer having discrete phase segments, the discrete phase segments being immiscible with the matrix copolymer, the modifier polymer further comprising anchor segments that are miscible with the matrix copolymer,

wherein the modifier polymer is a biodegradable polymer,

wherein a plurality of bioceramic particles are dispersed within the continuous and/or the discrete phase,

wherein the bioceramic/polymer composite is between 0.5% and 2% bioceramic particles by weight as compared to the polymers of the composite.

2. The device of claim 1, wherein all or a majority of the continuous phase comprises the matrix copolymer.

3. The device of claim 1, wherein the discrete phase segments have a Tg below human body temperature.

4. The device of claim 1, wherein the discrete phase segments comprise elastomeric functional groups.

5. The device of claim 1, wherein the discrete phase segments comprise monomers selected from the group consisting of caprolactone, trimethylene carbonate, and glycolide.

6. The device of claim 1, wherein the modifier polymer is selected from the group consisting of poly(glycolide-co-ε

-caprolactone)-b-poly(L-lactide), poly(glycolide-co-ε

-caprolactone)-b-poly(L-lactide-co-glycolide), and a combination thereof.

7. The device of claim 1, wherein the bioceramic particles are nanoparticles.

8. The device of claim 1, wherein the bioceramic particles are biodegradable.

9. The device of claim 1, wherein the degradation products of the bioceramic particles are capable of modifying a degradation rate of the matrix polymer and/or the modifier polymer during use of the device.

10. The device of claim 1, wherein the bioceramic particles are selected from the group consisting of calcium sulfate and hydroxyapatite.

11. The device of claim 1, wherein a surface of the bioceramic particles comprises an adhesion promoter, the adhesion promoter enhancing bonding between the matrix and/or the modifier polymer and the bioceramic particles.

12. The device of claim 1, wherein the particles increase the toughness and modulus of the scaffolding of the device at physiological conditions.

13. The device of claim 1, wherein the discrete phase further comprises a copolymer comprising discrete phase segments with no anchor segments.

14. The device of claim 1, wherein 1 to 40 wt % of the scaffolding comprises the modifier polymer.

15. The device of claim 1, wherein the scaffolding is 5-20 wt % of the modifier polymer and about 75-95 wt % of the matrix polymer.